Merck & Company, Inc. (NYSE:MRK) – Analysts at SunTrust Banks lowered their Q3 2017 earnings estimates for Merck & in a note issued to investors on Monday. SunTrust Banks analyst J. Boris now forecasts that the company will earn $1.00 per share for the quarter, down from their prior forecast of $1.01. SunTrust Banks also issued estimates for Merck &’s Q4 2017 earnings at $1.00 EPS, FY2019 earnings at $4.45 EPS and FY2021 earnings at $5.49 EPS.
Several other research firms also recently weighed in on MRK. BMO Capital Markets reaffirmed a “buy” rating and issued a $74.00 price target on shares of Merck & in a research note on Tuesday, June 27th. BidaskClub raised shares of Merck & from a “sell” rating to a “hold” rating in a research note on Thursday, June 22nd. Zacks Investment Research downgraded shares of Merck & from a “hold” rating to a “sell” rating in a research note on Wednesday, October 11th. Citigroup Inc. set a $65.00 price target on shares of Merck & and gave the company a “hold” rating in a research note on Wednesday, July 5th. Finally, UBS AG lifted their price target on shares of Merck & from $70.00 to $72.00 and gave the company a “buy” rating in a research note on Monday, July 31st. Two research analysts have rated the stock with a sell rating, seven have issued a hold rating and eleven have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $70.50.
WARNING: “Merck & Company, Inc. (MRK) Forecasted to Earn Q3 2017 Earnings of $1.00 Per Share” was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this report on another domain, it was illegally copied and reposted in violation of U.S. & international copyright & trademark legislation. The correct version of this report can be read at https://www.dispatchtribunal.com/2017/10/28/merck-company-inc-mrk-forecasted-to-earn-q3-2017-earnings-of-1-00-per-share.html.
Merck & (NYSE MRK) opened at 63.51 on Wednesday. The company has a 50-day moving average of $64.55 and a 200-day moving average of $63.70. The firm has a market capitalization of $173.21 billion, a price-to-earnings ratio of 34.39 and a beta of 0.80. Merck & has a 52 week low of $58.29 and a 52 week high of $66.80.
Merck & (NYSE:MRK) last announced its earnings results on Friday, July 28th. The company reported $1.01 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.87 by $0.14. The firm had revenue of $9.93 billion during the quarter, compared to analyst estimates of $9.75 billion. Merck & had a net margin of 17.14% and a return on equity of 26.02%. The company’s revenue for the quarter was up .9% compared to the same quarter last year. During the same period in the prior year, the business earned $0.93 EPS.
A number of institutional investors have recently added to or reduced their stakes in MRK. Hexavest Inc. boosted its holdings in Merck & by 4.9% during the first quarter. Hexavest Inc. now owns 1,560,798 shares of the company’s stock worth $99,173,000 after purchasing an additional 73,342 shares during the last quarter. Stewart & Patten Co. LLC boosted its holdings in Merck & by 4.1% during the first quarter. Stewart & Patten Co. LLC now owns 7,767 shares of the company’s stock worth $494,000 after purchasing an additional 304 shares during the last quarter. Retirement Systems of Alabama boosted its holdings in Merck & by 1.2% during the first quarter. Retirement Systems of Alabama now owns 1,710,361 shares of the company’s stock worth $108,676,000 after purchasing an additional 20,348 shares during the last quarter. OLD Point Trust & Financial Services N A boosted its holdings in Merck & by 1.0% during the first quarter. OLD Point Trust & Financial Services N A now owns 31,299 shares of the company’s stock worth $1,988,000 after purchasing an additional 300 shares during the last quarter. Finally, Hudson Valley Investment Advisors Inc. ADV boosted its holdings in Merck & by 2.3% during the first quarter. Hudson Valley Investment Advisors Inc. ADV now owns 66,891 shares of the company’s stock worth $4,250,000 after purchasing an additional 1,495 shares during the last quarter. Institutional investors and hedge funds own 72.86% of the company’s stock.
The company also recently declared a quarterly dividend, which was paid on Friday, October 6th. Investors of record on Friday, September 15th were issued a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a yield of 2.96%. The ex-dividend date was Thursday, September 14th. Merck &’s dividend payout ratio (DPR) is presently 76.11%.
About Merck &
Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.
Receive News & Ratings for Merck & Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Company Inc. and related companies with MarketBeat.com's FREE daily email newsletter.